ERBB2 and breast cancer: The main chemical associated with the shared DEGs was fulvestrant, a selective estrogen receptor degrader (SERD), used as a medication to treat hormone receptor (HR)-positive metastatic breast cancer in postmenopausal women with disease progression as well as HR-positive, HER2-negative advanced breast cancer in combination with palbociclib in women with disease progression after endocrine therapy [29,30].